Fibroblast phenotypes and their activity are changed in the wound healing process after lung transplantation

Andersson-Sjöland, Annika; Thiman, Lena; Nihlberg, Kristian; Hällgren, Oskar; Rolandsson, Sara; Skog, Ingrid; Mared, L.; Hansson, Lennart; Eriksson, Leif; Bjermer, Leif; Westergren‐Thorsson, Gunilla

doi:10.1016/j.healun.2011.04.006

Cited by 19 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 20 Increased biglycan was found in central airways and alveolar parenchyma of patients with uncontrolled asthma. 21 Furthermore, fibroblasts isolated from patients who developed BOS were shown to be more responsive to TGF-β1-induced biglycan expression compared with stable patients. 22 The systematic quantification of these proteins revealed a time-specific and localisation-specific pattern of ECM changes, which differed between patients who did or did not develop BOS.…”

Section: Key Messagesmentioning

confidence: 99%

“…Antibodies were assessed for specificity and optimal antigen retrieval methods. 21 Antigen retrieval was performed with 0.2% bovine testicular hyaluronidase (Sigma type I-S, buffer 20mM sodium acetate, 150mM sodium chloride, pH 5.2) for 30 min and subsequently with 20 µg/mL protease XXIV in PBS (Subtilisin, Carlsberg, Sigma) for 20 min (both room temperature). Primary antibodies against col IV α1 chain (Abcam 6586, concentration 1 mg/mL, used at 1:4000) and biglycan (Atlas antibodies, Uppsala, Sweden, HPA003157, concentration 0.1 mg/mL, used at 1:1750) were incubated for 1 hour at room temperature.…”

Section: Immunohistochemistrymentioning

confidence: 99%

See 1 more Smart Citation

Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundChronic lung allograft dysfunction in the form of bronchiolitis obliterans syndrome (BOS) is the main cause of death beyond 1-year post-lung transplantation. The disease-initiating triggers as well as the molecular changes leading to fibrotic alterations in the transplanted lung are largely unknown. The aim of this study was to identify potential early changes in the extracellular matrix (ECM) in different compartments of the transplanted lung prior to the development of BOS.MethodsTransbronchial biopsies from a cohort of 58 lung transplantation patients at the Copenhagen University hospital between 2005 and 2006, with or without development of BOS in a 5-year follow-up, were obtained 3 and 12 months after transplantation. Biopsies were assessed for total collagen, collagen type IV and biglycan in the alveolar and small airway compartments using Masson's Trichrome staining and immunohistochemistry.ResultsA time-specific and compartment-specific pattern of ECM changes was detected. Alveolar total collagen (p=0.0190) and small airway biglycan (p=0.0199) increased between 3 and 12 months after transplantation in patients developing BOS, while collagen type IV (p=0.0124) increased in patients without BOS. Patients with early-onset BOS mirrored this increase. Patients developing grade 3 BOS showed distinct ECM changes already at 3 months. Patients with BOS with treated acute rejections displayed reduced alveolar total collagen (p=0.0501) and small airway biglycan (p=0.0485) at 3 months.ConclusionsPatients with future BOS displayed distinct ECM changes compared with patients without BOS. Our data indicate an involvement of alveolar and small airway compartments in post-transplantation changes in the development of BOS.

show abstract

Section: Key Messagesmentioning

confidence: 99%

Section: Immunohistochemistrymentioning

confidence: 99%

Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In response to tissue damage or inflammation, fibroblasts and ASM cells are also able to release angioregulatory molecules, such as VEGF, to stimulate remodelling of the vascular network [30][31][32]. During wound healing fibroblasts may change phenotype to a non-proliferative and extracellular matrix (ECM)-producing cell [33].…”

Section: Endothelial Cells Airway Smooth Muscle Cells and Fibroblastsmentioning

confidence: 99%

Pulmonary vascular changes in asthma and COPD

Harkness

Kanabar

Sharma

et al. 2014

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

In chronic lung disorders such as in asthma and chronic obstructive pulmonary disease (COPD) there is increased bronchial angiogenesis and remodelling of pulmonary vessels culminating to altered bronchial and pulmonary circulation. The involvement of residential cells such as endothelial cells, smooth muscle cells and pulmonary fibroblasts, all appear to have a crucial role in the progression of vascular inflammation and remodelling. The regulatory abnormalities, growth factors and mediators implicated in the pulmonary vascular changes of asthma and COPD subjects and potential therapeutic targets have been described in this review.

show abstract

“…Moreover, the up-regulation of versican was more significant in patients developed bronchiolitis obliterans. Versican is considered TLR2 agonist (8).…”

Section: Effects Of Ischemic-reperfusion Injurymentioning

confidence: 99%

Could Ex Vivo Lung Perfusion Be a Platform to Decrease the Incidence of Chronic Lung Allograft Dysfunction?

Mohamed

2015

Archives of Medical Research

View full text Add to dashboard Cite

Fibroblast phenotypes and their activity are changed in the wound healing process after lung transplantation

Cited by 19 publications

References 29 publications

Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation

Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation

Pulmonary vascular changes in asthma and COPD

Could Ex Vivo Lung Perfusion Be a Platform to Decrease the Incidence of Chronic Lung Allograft Dysfunction?

Contact Info

Product

Resources

About